Copyright
©The Author(s) 2022.
World J Diabetes. May 15, 2022; 13(5): 387-407
Published online May 15, 2022. doi: 10.4239/wjd.v13.i5.387
Published online May 15, 2022. doi: 10.4239/wjd.v13.i5.387
Cannabinoid agent | Mechanism | Effect |
Endocannabinoids | Oxidative/Nitrative stress | Influenced ROS and RNS production[28] |
Myocardial remodeling | Triggered activation of signaling pathways (e.g., p38 and JNK-MAPKs), promoting cell death[50,137] | |
Inflammation | Increased during inflammation[107] | |
Modulating T and B lymphocyte proliferation and apoptosis, inflammatory cytokine production and immune cell activation by inflammatory stimuli[107,108,111] | ||
AM281 | Oxidative/Nitrative stress | Attenuated doxorubicin-induced oxidative stress[52] |
SR141716A | Oxidative/Nitrative stress | Attenuated doxorubicin-induced oxidative stress[52] |
Inflammation | Reduced plasma levels of the pro-inflammatory cytokines MCP-1 and IL-12 in low density lipoprotein deficient mice[113] | |
Inhibited LPS-induced pro-inflammatory IL-6 and TNF-α expression[113] | ||
Myocardial remodeling | Reduced activation of p38 and JNK/MAPK[90] | |
Improved myocardial dysfunction induced in a mouse model of diabetic cardiomyopathy[92] | ||
Reduced markers of cell death (activated caspase-3 and chromatin fragmentation)[92] | ||
JWH133 | Oxidative/Nitrative stress | Reduced ROS release in ApoE knockout mice[54] |
Inflammation | Decreased leukocyte recruitment in ApoE-knockout mice[54] | |
Attenuated TNF-α-induced NF-κB activation[116] | ||
Attenuated ICAM-1 and VCAM-1 up-regulation[116] | ||
Cannabidiol | Oxidative/Nitrative stress | Attenuated oxidative and nitrative stress in the myocardium of streptozotocin-induced diabetic mice[93] |
Prevented changes in markers of lipid peroxidation and oxidative stress in diabetic rats[96] | ||
Inflammation | Inhibited IκB-α phosphorylation and subsequent p65 NF-κB nuclear translocation[93] | |
Attenuated high glucose-induced NF-κB activation in primary human cardiomyocytes[93] | ||
Myocardial remodeling | Attenuated the established systolic and diastolic dysfunction in diabetic mice[93] | |
Attenuated the activation of stress signaling pathways: p38 and JNK/MAPKs[93] | ||
Enhanced the activity of the pro-survival AKT pathway in diabetic myocardium[93] | ||
Decreased the activity of the pro-apoptotic enzyme caspase-3[93] | ||
Autophagy | Promoted endothelial cell survival via HO-1 mediated autophagy[170] | |
Anandamide | Oxidative/Nitrative stress | Induced NO bioavailability[97] |
Myocardial remodeling | Decrease rat heart mitochondrial O2 consumption[135] | |
Increased activation of p38 and JNK/MAPK, followed by cell death[90] | ||
Enhanced doxorubicin-induced MAPK activation and cell death[90] | ||
Δ9-tetrahydrocannabinol (THC) | Oxidative/Nitrative stress | Regulated redox state in diabetic rats[96] |
Myocardial remodeling | Decreased rat heart mitochondrial O2 consumption[135] | |
WIN55, 212-2 | Inflammation | Reduced atherosclerotic lesion macrophage content and IL-6 and TNF-α levels[114,115] |
Reduced adhesion molecules VCAM-1 and ICAM-1 as well as NF-κB activation[114,115] | ||
HU-308 | Inflammation | Attenuated TNF-α-induced NF-κB activation, ICAM-1 and VCAM-1 up-regulation[116] |
Decreased endothelial cell activation and suppression of the acute inflammatory response[56,117] | ||
Autophagy | Enhanced autophagy levels in heart tissues with diabetic cardiomyopathy[171] | |
Increased AMPK phosphorylation while decreasing the phosphorylation of mTOR[171] | ||
HU-210 | Myocardial remodeling | Decrease rat heart mitochondrial O2 consumption[135] |
Increased activation of p38 and JNK/MAPK, followed by cell death[90] | ||
Enhanced doxorubicin-induced MAPK activation and cell death[90] | ||
Enhanced left ventricular performance in rats with myocardial infarction[143] | ||
AM251 | Myocardial remodeling | Improved cardiac function in carbon tetrachloride-induced cirrhosis in rats[140] |
Reduced activation of p38 and JNK/MAPK[90] |
- Citation: El-Azab MF, Wakiel AE, Nafea YK, Youssef ME. Role of cannabinoids and the endocannabinoid system in modulation of diabetic cardiomyopathy. World J Diabetes 2022; 13(5): 387-407
- URL: https://www.wjgnet.com/1948-9358/full/v13/i5/387.htm
- DOI: https://dx.doi.org/10.4239/wjd.v13.i5.387